CR10638A - Uso de derivados de azibiciclo hexano - Google Patents
Uso de derivados de azibiciclo hexanoInfo
- Publication number
- CR10638A CR10638A CR10638A CR10638A CR10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A
- Authority
- CR
- Costa Rica
- Prior art keywords
- azibiciclo
- hexan
- derivatives
- methyl
- oxaxol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a la sal de tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxaxol-5-il)-4H-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceticas, procedimientos para su preparacion y su uso en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0616574.0A GB0616574D0 (en) | 2006-08-21 | 2006-08-21 | Compounds |
PCT/EP2006/008314 WO2007022980A1 (en) | 2005-08-22 | 2006-08-21 | Use of azabicyclo hexane derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10638A true CR10638A (es) | 2009-03-20 |
Family
ID=37081324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10638A CR10638A (es) | 2006-08-21 | 2009-02-25 | Uso de derivados de azibiciclo hexano |
Country Status (22)
Country | Link |
---|---|
US (1) | US20080058398A1 (es) |
EP (1) | EP2054054A1 (es) |
JP (1) | JP5315244B2 (es) |
KR (1) | KR101495362B1 (es) |
CN (1) | CN101528221B (es) |
AR (1) | AR062471A1 (es) |
AU (1) | AU2007287527B2 (es) |
BR (1) | BRPI0716454A2 (es) |
CA (1) | CA2661437A1 (es) |
CL (1) | CL2007002422A1 (es) |
CO (1) | CO6150139A2 (es) |
CR (1) | CR10638A (es) |
EA (1) | EA017917B1 (es) |
GB (1) | GB0616574D0 (es) |
IL (1) | IL196976A0 (es) |
MA (1) | MA30672B1 (es) |
MX (1) | MX2009001941A (es) |
NO (1) | NO20090834L (es) |
PE (1) | PE20080609A1 (es) |
TW (1) | TW200825074A (es) |
WO (1) | WO2008022994A1 (es) |
ZA (1) | ZA200900886B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1946714B (zh) * | 2004-02-23 | 2011-06-15 | 葛兰素集团有限公司 | 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 |
GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
ATE484502T1 (de) * | 2005-06-14 | 2010-10-15 | Glaxo Group Ltd | Neue verbindungen |
GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
ATE487715T1 (de) * | 2005-08-22 | 2010-11-15 | Glaxo Group Ltd | Triazolderivate als modulatoren von dopamin-d3- rezeptoren |
GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
DE602007012531D1 (de) * | 2006-04-03 | 2011-03-31 | Glaxo Group Ltd | Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren |
US8222266B2 (en) * | 2006-04-03 | 2012-07-17 | Glaxo Group Limited | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
WO2008153937A2 (en) * | 2007-06-06 | 2008-12-18 | Dov Pharmaceutical, Inc. | Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
TW202400577A (zh) | 2021-09-14 | 2024-01-01 | 美商美國禮來大藥廠 | Sstr4促效劑鹽 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4260941B2 (ja) * | 1998-11-09 | 2009-04-30 | 株式会社片山製薬所 | アゼチジン−3−オール |
AU3147800A (en) * | 1999-03-15 | 2000-10-04 | Novo Nordisk A/S | New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
CN1946714B (zh) * | 2004-02-23 | 2011-06-15 | 葛兰素集团有限公司 | 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 |
SE526837C2 (sv) * | 2004-02-24 | 2005-11-08 | Kongsberg Automotive Asa | Växelspakstransmission |
US20070249623A1 (en) * | 2004-06-30 | 2007-10-25 | Eli Lilly And Company Patent Division | 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate |
GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
-
2006
- 2006-08-21 GB GBGB0616574.0A patent/GB0616574D0/en not_active Ceased
-
2007
- 2007-08-17 PE PE2007001117A patent/PE20080609A1/es not_active Application Discontinuation
- 2007-08-20 WO PCT/EP2007/058636 patent/WO2008022994A1/en active Application Filing
- 2007-08-20 CL CL200702422A patent/CL2007002422A1/es unknown
- 2007-08-20 US US11/841,015 patent/US20080058398A1/en not_active Abandoned
- 2007-08-20 EA EA200970211A patent/EA017917B1/ru not_active IP Right Cessation
- 2007-08-20 KR KR1020097003484A patent/KR101495362B1/ko not_active IP Right Cessation
- 2007-08-20 MX MX2009001941A patent/MX2009001941A/es active IP Right Grant
- 2007-08-20 EP EP07788490A patent/EP2054054A1/en not_active Withdrawn
- 2007-08-20 JP JP2009525046A patent/JP5315244B2/ja not_active Expired - Fee Related
- 2007-08-20 AU AU2007287527A patent/AU2007287527B2/en not_active Ceased
- 2007-08-20 BR BRPI0716454-8A2A patent/BRPI0716454A2/pt not_active IP Right Cessation
- 2007-08-20 CN CN2007800392082A patent/CN101528221B/zh not_active Expired - Fee Related
- 2007-08-20 TW TW096130644A patent/TW200825074A/zh unknown
- 2007-08-20 CA CA002661437A patent/CA2661437A1/en not_active Abandoned
- 2007-08-21 AR ARP070103715A patent/AR062471A1/es not_active Application Discontinuation
-
2009
- 2009-02-06 ZA ZA2009/00886A patent/ZA200900886B/en unknown
- 2009-02-09 IL IL196976A patent/IL196976A0/en unknown
- 2009-02-20 CO CO09017330A patent/CO6150139A2/es unknown
- 2009-02-23 NO NO20090834A patent/NO20090834L/no not_active Application Discontinuation
- 2009-02-25 CR CR10638A patent/CR10638A/es not_active Application Discontinuation
- 2009-02-27 MA MA31673A patent/MA30672B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090052327A (ko) | 2009-05-25 |
WO2008022994A1 (en) | 2008-02-28 |
PE20080609A1 (es) | 2008-07-26 |
KR101495362B1 (ko) | 2015-02-24 |
CO6150139A2 (es) | 2010-04-20 |
BRPI0716454A2 (pt) | 2014-03-04 |
EA200970211A1 (ru) | 2009-08-28 |
AR062471A1 (es) | 2008-11-12 |
CN101528221B (zh) | 2013-05-08 |
US20080058398A1 (en) | 2008-03-06 |
IL196976A0 (en) | 2009-11-18 |
JP5315244B2 (ja) | 2013-10-16 |
MA30672B1 (fr) | 2009-08-03 |
CL2007002422A1 (es) | 2008-03-14 |
TW200825074A (en) | 2008-06-16 |
MX2009001941A (es) | 2009-03-05 |
EA017917B1 (ru) | 2013-04-30 |
GB0616574D0 (en) | 2006-09-27 |
EP2054054A1 (en) | 2009-05-06 |
NO20090834L (no) | 2009-03-19 |
JP2010501519A (ja) | 2010-01-21 |
CN101528221A (zh) | 2009-09-09 |
AU2007287527A1 (en) | 2008-02-28 |
ZA200900886B (en) | 2011-05-25 |
AU2007287527B2 (en) | 2013-01-31 |
CA2661437A1 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10638A (es) | Uso de derivados de azibiciclo hexano | |
EA201000486A1 (ru) | Ингибитор белка, активирующего 5-липоксигеназу (flap) | |
UY32461A (es) | Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida | |
BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
CR11333A (es) | cis-IMIDAZOLINAS QUIRALES | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
UA100996C2 (ru) | Фармацевтически приемлемые соли метил-(3-([[3-(6-амино-2-бутокси-8-оксо-7,8-дигидро-9h-пурин-9-ил)-пропил]-(3-морфолин-4-илпропил)-амино]-метил)-фенил)-ацетата и их применение в терапии | |
NI201000079A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos. | |
TW200745099A (en) | Optically active thiazolidinedione derivatives | |
ZA200710513B (en) | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)-phenyl]-1, 1, 1-trifluoromethanesulfonamide derivatives | |
EA200800542A1 (ru) | Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4) | |
SV2005002148A (es) | "compuestos moduladores de la actividad c-kit y usos de los mismos" | |
NI200900040A (es) | Derivados de quinazolinona 5-substituidos como agentes antitumorales. | |
AR067540A1 (es) | Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende | |
NO20091413L (no) | WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser | |
ATE527262T1 (de) | Neue tomaymycin derivate enhaltende zytotoxische mittel | |
BRPI0615898B8 (pt) | composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
UA101346C2 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды | |
PH12015501955A1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
PL1771069T3 (pl) | Pochodne N-(2-(hydroksymetylo)fenylo)-1H-pirazolo-4-karboksamidu i związki pokrewne jako mikrobójcze substancje czynne do zastosowania w ochronie roślin i materiałów | |
UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
SG164283A1 (en) | New benzimidazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |